Skip to content
Head to head

Dyne Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: DYN · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

DYN -23.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
DYNVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price15.50515.02
Change today-3.31%-1.08%
1-year return-23.0%+22.0%
Market cap$2.90B$130.58B
52-week range14.00 – 27.31412.27 – 568.67
Valuation
P/E (TTM)-4.2833.14
P/E percentile, own 5-yr range38th99th
P/B3.126.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.4715.32
Net profit (TTM)$-650.23M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin39.4%85.5%
Operating margin-1.8%33.1%
Net margin1.2%30.7%
Free cash flow (TTM)$-568.76M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership103.7%96.8%
Insider activity (12mo)15 buy / 35 sell28 buy / 22 sell
Short interest (% of float)13.1%1.9%
Analyst consensus90% buy / 10% sell (10)95% buy / 5% hold (21)
Analyst price target$35 (+125%)$624 (+21%)
StockVane view
StockVane Quant RatingD (17)C (68)
Company
Employees2586,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.